CN115942976A - 掩蔽的il-2细胞因子和其切割产物 - Google Patents

掩蔽的il-2细胞因子和其切割产物 Download PDF

Info

Publication number
CN115942976A
CN115942976A CN202180039119.8A CN202180039119A CN115942976A CN 115942976 A CN115942976 A CN 115942976A CN 202180039119 A CN202180039119 A CN 202180039119A CN 115942976 A CN115942976 A CN 115942976A
Authority
CN
China
Prior art keywords
cytokine
masked
seq
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039119.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·罗森菲尔德
U·埃斯基欧卡克
邱华伟
P·约翰逊
K·A·詹金斯
M·珀德佐利-里贝尔
D·S·托玛
R·K·奥唐奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silio Development Co
Original Assignee
Silio Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silio Development Co filed Critical Silio Development Co
Publication of CN115942976A publication Critical patent/CN115942976A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)
CN202180039119.8A 2020-04-01 2021-03-31 掩蔽的il-2细胞因子和其切割产物 Pending CN115942976A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003824P 2020-04-01 2020-04-01
US63/003,824 2020-04-01
US202063118571P 2020-11-25 2020-11-25
US63/118,571 2020-11-25
PCT/US2021/025103 WO2021202675A1 (en) 2020-04-01 2021-03-31 Masked il-2 cytokines and their cleavage products

Publications (1)

Publication Number Publication Date
CN115942976A true CN115942976A (zh) 2023-04-07

Family

ID=77928454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039119.8A Pending CN115942976A (zh) 2020-04-01 2021-03-31 掩蔽的il-2细胞因子和其切割产物

Country Status (13)

Country Link
US (1) US20230151072A1 (https=)
EP (1) EP4126247A4 (https=)
JP (1) JP7735306B2 (https=)
KR (1) KR20220161404A (https=)
CN (1) CN115942976A (https=)
AU (1) AU2021245922A1 (https=)
BR (1) BR112022019689A2 (https=)
CA (1) CA3172649A1 (https=)
IL (1) IL296915A (https=)
MX (1) MX2022012311A (https=)
PH (1) PH12022552627A1 (https=)
TW (1) TW202204388A (https=)
WO (1) WO2021202675A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007838A1 (zh) * 2023-07-04 2025-01-09 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2021207669A1 (en) * 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023164286A1 (en) * 2022-02-28 2023-08-31 Xilio Development, Inc. Engineered cd122 compositions and methods thereof
JP2025508882A (ja) * 2022-02-28 2025-04-10 エクシリオ デベロップメント， インコーポレイテッド 標的化サイトカインおよびその使用方法
WO2024015960A1 (en) * 2022-07-15 2024-01-18 Xilio Development, Inc. Engineered cleavable fc domain as carriers and methods of use thereof
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025049948A1 (en) * 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
CA2878626A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CN108218993B (zh) 2018-01-05 2020-11-17 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的双特异性抗体及其制备和应用
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2020023702A1 (en) * 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20210221864A1 (en) * 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
US20220227837A1 (en) 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007838A1 (zh) * 2023-07-04 2025-01-09 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法
CN119546286A (zh) * 2023-07-04 2025-02-28 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法

Also Published As

Publication number Publication date
CA3172649A1 (en) 2021-10-07
AU2021245922A1 (en) 2022-10-13
US20230151072A1 (en) 2023-05-18
BR112022019689A2 (pt) 2022-12-20
IL296915A (en) 2022-12-01
MX2022012311A (es) 2023-01-05
EP4126247A1 (en) 2023-02-08
KR20220161404A (ko) 2022-12-06
JP7735306B2 (ja) 2025-09-08
EP4126247A4 (en) 2024-04-24
WO2021202675A1 (en) 2021-10-07
JP2023520517A (ja) 2023-05-17
PH12022552627A1 (en) 2023-01-04
TW202204388A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
JP7735306B2 (ja) マスクされたｉｌ－２サイトカイン及びその切断産物
JP7771076B2 (ja) マスクされたｉｌ－１２サイトカイン及びその切断産物
US20230331799A1 (en) Masked il-15 cytokines and their cleavage products
KR102874838B1 (ko) 마스킹된 사이토카인 폴리펩타이드
US12280120B2 (en) Tumor-specific cleavable linkers
CN113490687A (zh) 抗ctla4抗体和其使用方法
HK40092028A (zh) 掩蔽的il-2细胞因子和其切割产物
HK40090912A (zh) 掩蔽的il-15细胞因子和其切割产物
EA049880B1 (ru) Маскированные цитокиновые полипептиды

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092028

Country of ref document: HK